

Laila Staerk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1437939/publications.pdf>

Version: 2024-02-01

34
papers

1,182
citations

361413

20
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

2137
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. <i>European Heart Journal</i> , 2017, 38, ehw658.	2.2	142
2	Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. <i>BMJ</i> , The, 2015, 351, h5876.	6.0	120
3	Major Bleeding Complications and Persistence With Oral Anticoagulation in Nonvalvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	109
4	Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. <i>Journal of Internal Medicine</i> , 2018, 283, 45-55.	6.0	83
5	Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. <i>Scientific Reports</i> , 2016, 6, 31477.	3.3	80
6	Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , 2016, 38, ehw496.	2.2	74
7	Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 2707-2713.	2.0	45
8	On the estimation of average treatment effects with right-censored time to event outcome and competing risks. <i>Biometrical Journal</i> , 2020, 62, 751-763.	1.0	42
9	Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1790-1800.	2.8	41
10	Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2150-2158.	2.8	37
11	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study. <i>Scientific Reports</i> , 2017, 7, 3347.	3.3	36
12	Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1182-1191.	3.4	35
13	Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin - A Nationwide Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0141377.	2.5	31
14	Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. <i>European Heart Journal</i> , 2019, 40, 3782-3790.	2.2	29
15	Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2015, 17, 1215-1222.	1.7	28
16	Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. <i>European Heart Journal</i> , 2018, 39, 1698-1705a.	2.2	28
17	Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation. <i>Europace</i> , 2018, 20, e78-e86.	1.7	22
18	Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?. <i>Journal of Internal Medicine</i> , 2017, 282, 164-174.	6.0	21

#	ARTICLE	IF	CITATIONS
19	Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2291-2299.	3.4	21
20	Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006058.	2.2	21
21	Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 220-227.	3.0	20
22	Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 292-300.	3.0	20
23	Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1357-1365.	2.8	18
24	Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. <i>Heart</i> , 2018, 104, 912-920.	2.9	16
25	All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f93-f100.	3.0	16
26	Association Between Leukocyte Telomere Length and the Risk of Incident Atrial Fibrillation: The Framingham Heart Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	14
27	Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study. <i>Thrombosis Journal</i> , 2019, 17, 21.	2.1	14
28	Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	10
29	Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 20-30.	3.0	4
30	Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011–2016. <i>Thrombosis Research</i> , 2017, 160, 19-26.	1.7	3
31	Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation. <i>PLoS ONE</i> , 2016, 11, e0161768.	2.5	2
32	P6073 Increased major bleeding risk with use of topical miconazole agents among users of oral anticoagulation: A population-level safety study. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
33	3154 The incidence of atrial fibrillation continues to increase across all socioeconomic subgroups: 30-year time trends from a Nationwide cohort. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
34	Authors'™ reply to Beales. <i>BMJ, The</i> , 2016, 532, i266.	6.0	0